Related Experiment Video
Updated: Dec 7, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Cardiac Manifestations of Systemic Lupus Erythematous: An Overview of the Incidence, Risk Factors, Diagnostic
Nicole K Zagelbaum Ward1, Carlos Linares-Koloffon2, Alba Posligua3
1From the Department of Rheumatology, Keck School of Medicine/University of Southern California, Los Angeles, CA.
Insights
Systemic lupus erythematosus (SLE) can cause various heart problems, increasing patient risk. This review updates knowledge on SLE cardiac issues and current treatments, highlighting the need for further research on mortality impacts.
Area of Science:
- Rheumatology
- Cardiology
- Internal Medicine
Background:
- Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease.
- Cardiac involvement is a frequent and serious complication of SLE.
- SLE-related heart disease contributes significantly to patient morbidity and mortality.
Purpose of the Study:
- To provide a comprehensive review of cardiac manifestations in SLE.
- To update current understanding of SLE heart disease management.
- To discuss the impact of SLE treatments on cardiac outcomes.
Main Methods:
- Literature review of systemic lupus erythematosus and cardiac disease.
- Analysis of current therapeutic agents for SLE.
- Evaluation of cardiovascular risk factors and outcomes in SLE patients.
Main Results:
- SLE can manifest in various cardiac forms: pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias.
- Heart disease in SLE is linked to higher morbidity and mortality rates.
- The efficacy of traditional coronary artery disease treatments in SLE patients remains uncertain.
Conclusions:
- Cardiac complications are a major concern in SLE management.
- Current SLE therapies include glucocorticoids, hydroxychloroquine, and various immunosuppressants.
- Further research is needed to clarify the impact of treatments on cardiovascular mortality in SLE.
Abstract:
Systemic lupus erythematosus (SLE) is a complex connective tissue disease that can potentially affect every organ of the human body. In some cases, SLE may present with diverse cardiac manifestations including pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias. Heart disease in SLE is associated with increased morbidity and mortality. It is unclear whether traditional treatments for coronary artery disease significantly impact mortality in this population. Current therapeutic agents for SLE include glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and B cell-directed therapies. This article will provide a comprehensive review and update on this important disease state.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy

